Vulval cancers account for only 2-5% of all gynaecological malignancies with squamous cell carcinoma (SCC) being the most common subtype. Treatment is predominantly surgical however concurrent chemoradiotherapy (CTRT) is also an alternative for advanced tumours. We present our experience in SCC vulva cases diagnosed and operated at TMC, Kolkata (TMCK). The objective was to study the clinical profile and treatment outcome of operated vulval SCC with multimodal therapy at TMCK. This was a retrospective study with data collected from the hospital electronic medical records. The inclusion criterion was all histologically confirmed vulval SCC cases operated at TMCK with the study period from August 2011 to September 2019. A total number of 40 patients met criteria. The median age of the patients was 63.5 years with good PS in all except one patient. However 72.5% patients had associated co-morbidities. Majority 40% patients belonged to stage I followed by stage III (35%). 5% patients belonged to stages II and IV whereas 15% patients remained unstaged. Most common surgery performed was modified radical vulvectomy (MRV) + B/L groin node dissection (GND) in 15 (37.5%) followed by MRV in 20% patients. 15% also underwent reconstructive surgery and 2.5% underwent exenteration. Wound dehiscence was seen in 42.5% patients. Postoperatively adjuvant treatment was indicated in 50% patients but received in only 30% (20% radiotherapy and 10% chemoradiotherapy). On follow up, 67% patients were alive without disease, 10% alive with disease, 32.5% recurred amongst which 30.7% had a second recurrence. 15% patients died whereas 7.5% were lost to follow up. The estimated 5 year recurrence free survival (RFS) was 70% whereas the estimated 5 year overall survival (OS) was 85%.
